Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

33.35 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months ↗

September 28, 2026

Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s...

Via MarketBeat

Topics Government

There are notable gap-ups and gap-downs in today's session. ↗

September 08, 2026

Via Chartmill

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately ↗

August 28, 2026

Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered...

Via MarketBeat

Topics Government

Roivant Sciences Q1 Earnings Call Highlights ↗

August 07, 2026

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions...

Via MarketBeat

Topics Earnings Government

ROIVANT SCIENCES LTD (NASDAQ:ROIV) Flashes Strong Breakout Setup with Near-Perfect Technical and Setup Quality Ratings ↗

May 14, 2026

Via Chartmill

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗

February 06, 2026

Via Stocktwits

Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? ↗

July 07, 2026

Wall Street expects sales to soar as several commercial launches approach.

Via The Motley Fool

Roivant (ROIV) Q4 2025 Earnings Transcript ↗

May 20, 2026

Roivant (ROIV) Q4 2025 Earnings Transcript

Via The Motley Fool

Roivant Sciences Q4 Earnings Call Highlights ↗

May 20, 2026

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...

Via MarketBeat

Topics Earnings Government

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 20, 2026

Via Chartmill

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗

May 18, 2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Via The Motley Fool

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗

May 18, 2026

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares ↗

May 16, 2026

This biotech firm develops immunotherapies for cancer and autoimmune diseases, with several candidates advancing through clinical trials.

Via The Motley Fool

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...

Via MarketMinute

Topics Intellectual Property

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗

March 04, 2026

BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more...

Via The Motley Fool

Topics Regulatory Compliance

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

March 04, 2026

The news is likely to come as a relief to many investors, Citi told investors in a research note.

Via Stocktwits

Topics Intellectual Property

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Via Stocktwits

Topics Intellectual Property

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗

February 13, 2026

This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.

Via The Motley Fool

Topics Regulatory Compliance

TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth ↗

February 13, 2026

TTM Technologies supplies advanced printed circuit boards and RF components for high-reliability applications across diverse industries.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗

February 13, 2026

American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.

Via The Motley Fool

Topics Regulatory Compliance

The market is filled with gapping stocks in Friday's session. ↗

February 06, 2026

Via Chartmill

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 06, 2026

Via Chartmill

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.